Immunotherapy may be targeted against the immune checkpoint proteins such as programmed death ligand 1 (PD-L1), which have been frequently found expressed in CTCs of NSCLC and TNBC [3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.